Articles

KUALA LUMPUR, 22 OCTOBER 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) was recently recognised as the overall winner at the Sustainable Business Awards Malaysia (SBA) 2020/21 under the Large Organisation category, identifying the company as Malaysia’s leading organisation for sustainability practices. At this year’s event, Duopharma Biotech took home five trophies, in the categories of “Business Ethics & Responsibility”, “Stakeholder Management” and “UN Sustainable Development Goals” as well as receiving the Significant Achievement award in the “Water Management” and “Waste Productivity & Materiality” categories. The awards were presented in the presence of Dato’ Sri Mustapa Mohamed, Minister in the Prime Minister’s Department (Economy). 

KUALA LUMPUR, 15 October 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) is further strengthening COVID-19 vaccination efforts in Malaysia with the distribution of the Sinopharm COVID-19 vaccine. Earlier, Duopharma Biotech had entered into an agreement to import the vaccine from Beijing, China, covering a collaboration for the Malaysian market. Duopharma (M) Sdn. Bhd., a wholly owned subsidiary of Duopharma Biotech has been authorised by Sinopharm as the product registration holder and to engage in the sales and distribution of the vaccine.

• 2Q PBT rises 4.2% to RM20.2 million as compared to previous corresponding quarter
• Declares interim dividend of 0.5 sen per share
• Increased Federal Government budget allocation for healthcare sector and extension of public sector supply
agreements to boost future earnings

KUALA LUMPUR, 13 August 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or
“the Company”) held a fully virtual Meeting of Members today, which saw the shareholders
voting to approve the 1-for-3 bonus share issuance which the Company had proposed on 3
May 2021.

“As exemplified by the CERDIK initiative, closing the digital gap and promulgating digital
learning are among key catalysts required to inclusively build an essential talent platform for
our nation’s growth into the global digital economy,” says Duopharma Biotech Group MD

KUALA LUMPUR, 16 July 2021 – Duopharma (M) Sendirian Berhad, a wholly-owned
subsidiary of Duopharma Biotech Berhad (“Duopharma Biotech”), has been granted

conditional registration approval by Malaysia’s Drug Control Authority (“DCA”) for the Covid-
19 Sinopharm vaccine developed by China National Biotec Group Company Limited

(“Sinopharm CNBG”).

Following last year’s SAFE funding round, Duopharma Biotech delivers a further boost via a Series A funding round of Naluri Hidup to enhance homegrown health-tech
‘This is another milestone in Duopharma Biotech’s digital technology journey,’ says Group MD

● Following the signing with the Government of Malaysia, Duopharma Biotech’s Group MD
confirmed the Company’s readiness and alignment with Malaysia’s COVID-19 national
immunisation programme

➢ Duopharma Biotech Berhad’s 20th AGM reinforces the Group’s role as a pharmaceutical and
healthcare leader committed to actively supporting the health and betterment of Malaysia
through the coronavirus crisis and beyond
➢ Robust business fundamentals and core values of the Group continue to maintain our
forward momentum and to enable ventures into specialist and niche biotherapies, said
Duopharma Biotech leadership

➢ The 1-for-3 proposed bonus issue would entail the issuance of up to 239,926,896 new
ordinary shares
➢ 1Q 2021 PBT leaps to RM23.18 million, soaring more than 30% from the RM17.73 million
posted in the preceding year corresponding period
➢ Record profits posted on back of increased quarterly revenue of RM166.45 million (2020:
RM158.71 million)